Projects

EFCCA PROJECTS DIGEST Newsletter

The new issue of our PROJECTS DIGEST is now online! Download it here: Issue #3 (February 2024)   We are delighted to present to you the EFCCA PROJECTS DIGEST. This newsletter will include information regarding the 5 Horizon Europe projects, 2 Horizon 2020 projects, and other projects that EFCCA is presently engaged in. The PROJECTS DIGEST will be published every 2-...

EFCCA Empowerment Academy

We launched our EFCCA Empowerment Academy, a training programme tailored for recent EFCCA members designed to offer deeper insights into the organisation. The programme provides participants with a global learning journey led by EFCCA staff and other experts. Encompassing subjects like law, corporate governance, organisational history or ethics, it guarantees a comprehensive comprehension...

World IBD Day 2024

Join us in celebrating World IBD Day 2024! A Global Movement for Accessible IBD Care   We are pleased to announce EFCCA's plans for World IBD Day 2024, united under the theme: "IBD Has No Borders." This year, our focus is on strengthening global alliances and amplifying our collective impact in the fight against Inflammatory Bowel Disease (IBD...

World IBD Day

World IBD Day takes place on 19 May each year and unites people worldwide in their fight against Crohn's disease and ulcerative colitis, known as inflammatory bowel diseases (IBD). This year our theme for World IBD Day is IBD HAS NO BORDERS : World IBD Day 2024 Purple Ribbon Awareness Many of the IBD associations linked to World IBD Day are using the purple ribbon as a symbol of...

Horizon Europe - FIBROTARGET

EFCCA is involved in an exciting new Horizon Europe project called FIBROTARGET. This project aims to validate novel immunotherapeutic targets against fibrosis in inflammatory bowel disease in order to obtain patients and regulatory approval for implementation of these novel noninvasive imaging modalities as diagnostic and prognostic tools for fibrotic IBD. This will allow vital future therapeutic...

Horizon Europe - miGut

We take great pleasure in informing you that EFCCA is one of the 12 partners coming from 9 countries of the consortium for the miGut-Health Project, which has been selected for European funding under the Horizon 2020 framework. This project will strive to empower people living with IBD by creating state-of-the-art strategies for early disease prediction, prevention, and health monitoring. This...

Horizon Europe - METHYLOMIC

The METHYLOMIC project will build on multiple previous cohort studies that confirmed epigenetic biomarkers (specifically DNA methylation) as the most stringent predictor of response to biological therapy, zooming in on CD. DNA methylation profiles in peripheral blood as biomarkers of response/deep remission for three approved biologicals in CD have been specifically discovered and validated....

Horizon Europe - GlycanTrigger

The GlycanTrigger project proposes a thorough and innovative approach to understand better the health-to-chronic inflammation transition occurring in patients with CD that will be translated into improved disease prediction and prevention. The project aims to do so by addressing how changes in glycosylation of the gut mucosa act as a primary event that dysregulates not only local mechanisms (...

Horizon Europe - GENEGUT

The GENEGUT project will transform the treatment of ileal CD by developing a first-in-class oral RNA-based therapy, tackling inflammation locally in the intestinal tissue, while avoiding systemic side effects. Despite advances in new immune modulators and biological treatment, up to 30% of patients become non-responders. Besides, intestinal fibrosis is a significant challenge in Crohn’s...

Patient Preferences

  WHAT DO IBD PATIENTS FIND IMPORTANT IN THEIR TREATMENT? “What do you find important in your (IBD?) treatment?”, “Which quality of life effects are important to you?”, “Which side-effects do you want to avoid?”, “Which characteristics should future drugs have according to you?” To address these questions, EFCCA has embarked on exciting research with the University of Leuven (KU...